Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 4/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8283854 | 0.93 | CSF1R (0.53) | CSF1RALDH1A1POLBHTTNTRK1 | |
| SCHEMBL8284702 | 0.85 | ALDH1A1 (0.46) | CSF1RALDH1A1POLBHTTNTRK1 | |
| SCHEMBL8286215 | 0.85 | CSF1R (0.57) | CSF1RALDH1A1POLBHTTNTRK1 | |
| SCHEMBL8286204 | 0.82 | CSF1R (0.50) | CSF1RALDH1A1POLBHTT | |
| SCHEMBL12884201 | 0.80 | CSF1R (0.40) | CSF1RALDH1A1HTTHDAC1HDAC8 | |
| SCHEMBL12884197 | 0.80 | CSF1R (0.39) | CSF1RALDH1A1POLBHTTHDAC1 | |
| SCHEMBL8286213 | 0.79 | CSF1R (0.53) | CSF1RALDH1A1POLBHTT | |
| SCHEMBL8283857 | 0.79 | CSF1R (0.57) | CSF1RALDH1A1POLBHTTNTRK1 | |
| SCHEMBL8284699 | 0.79 | ALDH1A1 (0.40) | ALDH1A1POLBHTTHDAC1HDAC8 | |
| SCHEMBL8284701 | 0.77 | CSF1R (0.42) | CSF1RALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| US-8044073-B2 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | TIBOTEC PHARMACEUTICALS (IE) | 2011-10-25 | — | — | US | disclosed |
| EP-1697343-B1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2009-07-01 | — | — | EP | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN SCIENCES IRELAND UC (IE) | 2007-05-03 | — | — | US | disclosed |
| WO-2005058869-A1 | AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099924-A1 | Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 | CSF1R 4129/4885ALDH1A1 1319/4885POLB 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.